Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
May 18, 2023 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug...
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
November 08, 2022 16:00 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023.Next Generation Capecitabine (a combination of PCS6422 and...
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
November 08, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6...
Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
September 15, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is...
Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
September 07, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
May 05, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
April 20, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The amended protocol will provide a more precise...
Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
March 23, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
January 26, 2022 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet...